A shocking 89% plunge in MoonLake Immunotherapeutics' stock has sent shockwaves through the market, leaving investors reeling. The cause? Mixed results for their highly anticipated skin disease treatment, sonelokimab. But here's where it gets controversial...
MoonLake's trials aimed to tackle hidradenitis suppurativa (HS), a painful skin condition causing inflammation and scarring. While one final-phase study met its goal, the other fell short. The company had hoped to achieve a 75% reduction in inflammatory lesions, known as the HiSCR75 scale. In one study, sonelokimab showed a 17% improvement over the placebo, but in the second, only a 10.3% difference was observed.
Investors had expected a more significant gap, with a minimum 20% improvement between the treatment and placebo groups. This has led to a dramatic reaction in the stock market, with MoonLake Immunotherapeutics shares crashing to $6.60, an 89% drop.
The news has been a boost for Oruka Therapeutics, a competitor working on an HS treatment, with their stock surging over 16%.
But is this the full story?
Analysts are comparing MoonLake's results to UCB's Bimzelx, an approved HS treatment. While MoonLake's sonelokimab showed similar results in reducing lesions, it outperformed Bimzelx in patient-reported outcomes, safety, and convenience. This could potentially give MoonLake an edge in the market, especially with support from key opinion leaders.
However, Leerink Partners analyst Thomas Smith believes these results are "clearly disappointing" and expected a more significant impact. He predicted a weak outlook for MoonLake's shares, which has proven true.
Needham analyst Serge Belanger adds that the regulatory path forward is uncertain for sonelokimab. He questions its performance in current psoriatic arthritis trials, with results due in 2026. Belanger suggests MoonLake may need to conduct an additional Phase 3 study to gain approval for their HS drug.
So, is this a temporary setback or a sign of more significant issues? Will MoonLake be able to turn things around? And what does this mean for investors? These are questions that remain unanswered, leaving room for speculation and debate.
What are your thoughts? Do you think MoonLake can recover, or is this a sign of deeper problems? Share your insights and predictions in the comments below!
